Business
Impax, Stada, Taro may be takeover targets for Mylan, Perrigo; Mylan may also look for assets shed in Teva-Allergan deal
Hi, what are you looking for?
Impax, Stada, Taro may be takeover targets for Mylan, Perrigo; Mylan may also look for assets shed in Teva-Allergan deal
Mylan's Executive Chairman Robert Coury: we are well-positioned to quickly execute on the next strategic, value-enhancing opportunities for our business, some of which we...
Generic drug maker Mylan $26bn hostile bid for peer Perrigo looked unlikely to succeed, a few hours before it was set to expire, a...
Perrigo Company Plc, the Irish-based generic drugmaker trying to fend off a hostile bid by Mylan NV, held unsuccessful talks to acquire Endo International...
Abbott Laboratories (NYSE: ABT), said it would back the generic pharmaceutical company Mylan’s (MYL) $34 billion bid acquisition of Perrigo Co Plc (PRGO.N). Abbott...
Bolt-on acqusition strengthens position in Europe amid three-way takeover battle with Mylan and Teva
In the three way takeover battle Mylan is getting nervous.
Three Way Takeover Battle: believes their offer will win approval from Perrigo stockholders.
Teva Pharmaceutical Industries Ltd. has agreed to pay $1.2 billion in a settlement with the U.S. Federal Trade Commission (FTC), resolving claims that Cephalon...
Bloomberg reports Mylan chairman Robert Coury as telling investors he is prepared to reduce Perrigo shareholders' risk